153 / 490
151
SCIENTIFIC PROGRAMME
| PROGRAMME AND EXHIBITION GUIDE
TUESDAY 3 MAY 2016
09:45 > GWAS, SNPs and normal tissue toxicity for personalised radiation
oncology
Speaker: C. West (UK)
SP-0580
10:00 > Integrative data analysis for PRO
Speaker: M.A. Gambacorta (Italy)
SP-0581
10:15 > Gene signatures predict loco-regional control after postoperative radio-
chemotherapy in HNSCC
S. Schmidt (Germany), A. Linge, F. Lohaus, V. Gudziol, A. Nowak,
I. Tinhofer, V. Budach, A. Sak, M. Stuschke, P. Balermpas, C. Rödel,
M. Avlar, A.L. Grosu, A. Abdollahi, J. Debus, C. Belka, S. Pigorsch,
S.E. Combs, D. Mönnich, D. Zips, G.B. Baretton, F. Buchholz, M. Baumann,
M. Krause, S. Löck
OC-0582
Symposium
THE TUMOUR IN 3D: THE ROLE OF TUMOUR MICROENVIRONMENT
09:15 - 10:30 | LONDRA
The microenvironment is an integral part of normal and tumour tissue development, homeostasis and
3D architecture. For the generation of clinically relevant data, we need to take these characteristics into
consideration. Recent observations using 3D cell culture models provide evidence that the cellular
response to irradiation is similar to the effects seen in tissues and different from conventional 2D cell
cultures. In this symposium, we will show the advantage of 3D cell culture models over 2D and how
they can be used for (i) testing tumor and normal cell radiation responses with and without chemo-
therapy/novel molecular drugs and (ii) expansion of stem cells for therapy. Further, we will demonstrate
the differential impact of hypo- and hyperfractionation radiotherapy on the immune system.
Chair: N. Cordes (Germany)
Co-chair: G.L. Gravina (Italy)
09:15 > Relevance of 3D cultures to address radiation response and novel RT
combination strategies
Speaker: N. Cordes (Germany)
SP-0583
09:33 > The potential of normal tissue organoid cultures
Speaker: R. Coppes (The Netherlands)
SP-0584
09:51 > The impact of a novel 3D cell culture model of glioblastoma on radiation
and drug-radiation responses
Speaker: N. Gomez-Roman (UK)
SP-0585
10:09 > Radiotherapy supports tumour-specific immunity
Speaker: M. Van den Broek (Switzerland)
SP-0586